[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Pediatrics](https://durgical.com/en/pediatrics/) › [Bones and joints](https://durgical.com/en/pediatrics/areas/msk/) › Juvenile dermatomyositis

# Juvenile dermatomyositis

- Topic

Juvenile [dermatomyositis](https://durgical.com/en/conditions/inflammatory-myopathies/) is a rare autoimmune disease that inflames the skin, the muscles and the small blood vessels. Many need long treatment.

Updated Nov 20, 2026

## Key points

- Skin + muscle + vessels.
- Most common childhood myopathy, but rare.
- Anti-MDA5 = lung disease.
- Anti-NXP2 = calcinosis, dysphagia.
- Often chronic or relapsing.

On this page

- The basics Key points
- What it is
- How to think about it
- Key facts
- Step by step
- Myositis-specific autoantibodies in JDM
- Common traps

- Clinical In clinical practice

- Treatment Next step / Initial management

- Study Test yourself

- Connections Connections

## What it is

Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy of childhood, though still rare (about 3 per million children a year in the USA). It affects skin, muscle and blood vessels, with systemic features in some children. Its cause is not fully understood; immune dysregulation (especially of B cells), mitochondrial dysfunction, [neutrophil](https://durgical.com/en/immunology/neutrophil/) changes and increased interferon signalling are described. Myositis-specific autoantibodies define clinical subgroups: anti-TIF1 (the commonest) with photosensitivity, skin ulceration and chronic or polycyclic disease; anti-NXP2 with myalgia, dysphonia, dysphagia, calcinosis, more severe weakness and less remission; and anti-MDA5 (more common in Japan) with less weakness but [interstitial lung disease](https://durgical.com/en/conditions/interstitial-lung-disease/) and systemic features such as fever and weight loss. Most children do not fully respond to initial therapy and follow a chronic, refractory or polycyclic course.

## How to think about it

Think of JDM as a disease of small vessels that shows up in two places you can see and test: the skin and the muscles. The autoantibody is the label on the box: it predicts which other organs are at risk (lungs with anti-MDA5, calcinosis and swallowing with anti-NXP2, skin ulcers and chronic disease with anti-TIF1).

## Key facts

- Most common inflammatory myopathy of childhood, but rare.
- Involves skin, muscle and vessels; some children have lung, gut or heart involvement.
- Autoantibody subgroups predict features: anti-TIF1 (skin ulcers, chronic course), anti-NXP2 (calcinosis, dysphagia, severe weakness), anti-MDA5 (interstitial lung disease).
- First-line treatment is usually [corticosteroids](https://durgical.com/en/pharmacology/classes/corticosteroids/) with [methotrexate](https://durgical.com/en/pharmacology/methotrexate/); refractory disease needs other options, including biologics (no doses here).
- Most children have a chronic or relapsing course rather than a single episode.

## Step by step

- Suspect JDM in a child with muscle weakness and a skin rash.
- Measure muscle enzymes such as [creatine](https://durgical.com/en/biochemistry/molecules/creatine/) kinase and test myositis-specific autoantibodies.
- Screen for lung, swallowing, gut and heart involvement according to the subgroup.
- Start treatment with paediatric rheumatology per guideline.
- Monitor disease activity, growth and complications such as calcinosis.
- Plan long-term follow-up for a chronic or relapsing course.

## Myositis-specific autoantibodies in JDM

| Autoantibody | Frequency | Associated features |
| --- | --- | --- |
| Anti-TIF1 | Most common | Photosensitivity, skin ulceration, chronic or polycyclic course |
| Anti-NXP2 | Next most common | Myalgia, dysphonia, dysphagia, calcinosis, more severe weakness, less remission |
| Anti-MDA5 | More common in Japan | Less weakness; interstitial lung disease, fever, weight loss |

## In clinical practice

- Swallowing and voice problems signal more severe disease and aspiration risk.
- Calcinosis can appear during the course and affects function.

## Next step / Initial management

- Muscle enzymes (creatine kinase), myositis-specific autoantibodies, and imaging or tests for lung, gut and heart involvement by subgroup.
- Monitoring of disease activity and treatment side effects.
- Suspected JDM: refer to paediatric rheumatology; dysphagia, breathing problems or lung disease: urgent [referral](https://durgical.com/en/family-medicine/referral-and-counter-referral-from-the-doctor-s-side/).

## Common traps

- **JDM is the adult disease in a child**: it is a distinct childhood disease with its own autoantibody subgroups.
- **A child with weakness and a normal-looking skin cannot have JDM**: some subgroups have little weakness or mostly skin and lung disease.
- **One course of treatment cures most children**: most have a chronic, refractory or relapsing course.
- **The autoantibody result does not change care**: it predicts lung disease, calcinosis and the course.

## Test yourself

Think of the answer, then tap the question to see it.

## Which autoantibody in JDM is linked with interstitial lung disease?

Anti-MDA5.

## Which subgroup is associated with calcinosis and dysphagia?

Anti-NXP2.

## What course do most children with JDM follow?

A chronic, refractory or polycyclic course rather than full response to initial therapy.

[Add to my cards (3)](https://durgical.app/estudiar/?add=/en/pediatrics/juvenile-dermatomyositis/)

## Connections

## Related 2

- [A swollen joint in a child: first steps](https://durgical.com/en/pediatrics/a-swollen-joint-in-a-child-first-steps/)
- [The floppy infant: central or peripheral hypotonia?](https://durgical.com/en/pediatrics/the-floppy-infant-central-or-peripheral-hypotonia/)

[← All of pediatrics](https://durgical.com/en/pediatrics/)

Educational content; it does not replace assessment by a doctor and is not a clinical instruction. If a child has difficulty breathing, cannot drink, vomits everything, has a seizure, is very drowsy, or is a baby under three months with fever, go to an emergency department at once.

Sources: [Juvenile Dermatomyositis: Updates in Pathogenesis and Biomarkers, Current Treatment, and Emerging Targeted Therapies](https://europepmc.org/article/PMC/PMC11774970) (Paediatric Drugs (open access, Europe PMC), 2025).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/pediatrics/juvenile-dermatomyositis/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/pediatrics/juvenile-dermatomyositis/
